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Background: Chromosomal and genomic aberrations are common features of human cancers. However,
chromosomal numerical and structural aberrations, breakpoints and disrupted genes have yet to be identified in
esophageal squamous cell carcinoma (ESCC).
Methods: Using multiplex-fluorescence in situ hybridization (M-FISH) and oligo array-based comparative
hybridization (array-CGH), we identified aberrations and breakpoints in six ESCC cell lines. Furthermore, we detected
recurrent breakpoints in primary tumors by dual-color FISH.
Results: M-FISH and array-CGH results revealed complex numerical and structural aberrations. Frequent
gains occurred at 3q26.33-qter, 5p14.1-p11, 7pter-p12.3, 8q24.13-q24.21, 9q31.1-qter, 11p13-p11, 11q11-q13.4,
17q23.3-qter, 18pter-p11, 19 and 20q13.32-qter. Losses were frequent at 18q21.1-qter. Breakpoints that clustered
within 1 or 2 Mb were identified, including 9p21.3, 11q13.3-q13.4, 15q25.3 and 3q28. By dual-color FISH, we
observed that several recurrent breakpoint regions in cell lines were also present in ESCC tumors. In particular,
breakpoints clustered at 11q13.3-q13.4 were identified in 43.3% (58/134) of ESCC tumors. Both 11q13.3-q13.4
splitting and amplification were significantly correlated with lymph node metastasis (LNM) (P= 0.004 and 0.022) and
advanced stages (P= 0.004 and 0.039). Multivariate logistic regression analysis revealed that only 11q13.3-q13.4
splitting was an independent predictor for LNM (P= 0.026).
Conclusions: The combination of M-FISH and array-CGH helps produce more accurate karyotypes. Our data
provide significant, detailed information for appropriate uses of these ESCC cell lines for cytogenetic and molecular
biological studies. The aberrations and breakpoints detected in both the cell lines and primary tumors will
contribute to identify affected genes involved in the development and progression of ESCC.* Correspondence: wangmr2015@cicams.ac.cn
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Chromosomal and genomic rearrangements are signifi-
cant features of malignant human tumors. Rearrange-
ments are often associated with structural aberrations,
such as translocations, insertions and inversions. They
could also result in the copy number alterations (CNAs)
[1,2]. Characterizing rearrangements and genes affected
by the aberrations and breakpoints might help us to
understand tumor development and progression better.
The products and implications of chromosomal rear-
rangements (e.g., fusion genes, truncated genes, and
gene dysregulation by ectopic promoters) have been
described in leukemia, lymphoma, sarcomas, and epithe-
lial cancers [3,4]. It was initially difficult to detect
chromosomal rearrangements and affected genes in the
epithelial cancers, mainly due to the technical difficulty
of preparing metaphase spreads from primary epithelial
tumors and the karyotypic complexity. Until recently,
multiple gene rearrangements and even genomic land-
scapes which reflect the structural aberrations through-
out the genomes have been identified in multiple types
of epithelial cancers, including prostate cancer [5,6],
breast cancer [7,8], lung cancer [9,10], colorectal cancer
[11], gastric cancer [12], head and neck cancer [13],
hepatocellular carcinoma [14] and so on.
Recently, it has been reported that recurrent rearrange-
ments could affect genes at the boundaries of CNAs
[2,15], thus recurrent breakpoints might be important for
screening and identifying frequent unbalanced rearrange-
ments and the involved genes. Multiplex-fluorescence in
situ hybridization (M-FISH) [16] and spectral karyotyp-
ing (SKY) [17] were designed to replace traditional G-
banding in chromosomal analyses of tumor cells, but the
resolution of these techniques is not sufficient to detect
small rearrangements. Array-based comparative genomic
hybridization (array-CGH) was developed to analyze the
CNAs, including genomic gains, losses, amplifications
and deletions [18,19]. It was recently demonstrated that
array-CGH could be used to identify unbalanced break-
points of the rearrangements in many types of cancer
cells at a potentially higher resolution [20-24]. Array-
CGH has also been used, in combination with cyto-
genetic information, to determine the breakpoints in
reciprocal translocations [25].
Esophageal cancer (EC) is a common malignant epi-
thelial cancer worldwide, causing more than 40,000
deaths each year [26]. The most prevalent type of EC is
esophageal squamous cell carcinoma (ESCC), and China
is among the highest risk areas [26,27]. Recently, our
group reported the karyotype of ESCC cell line KYSE180
[28] and KYSE450 [29] by 12-color M-FISH, as well as
the karyotype of KYSE410-4 by 6-color M-FISH [30].
CGH [31-34], SKY and CGH [35], and array-CGH
[36-38] experiments from other groups have also beenperformed on ESCC cell lines and primary tumors.
These studies have revealed numerical and structural
chromosomal aberrations. However, genomic rearrange-
ments, breakpoints and genes that are involved in ESCC
remain to be decoded and clarified.
Our study intended to identify candidate recurrent
breakpoints which might affect genes at or near the
boundaries. In this study, we describe CNAs and unba-
lanced genetic rearrangements in six ESCC cell lines
through a combination of M-FISH and 44K array-CGH
techniques. We found recurrent breakpoint regions in
the cell lines and breakage of several regions present in
primary ESCC tumors, which may contribute to disrup-
tion of critical genes.
Methods
Cell lines and sample collection
ESCC cell lines KYSE30, KYSE150, KYSE180, KYSE450,
KYSE510 and YES2 were kindly provided by Yutaka Shi-
mada (Kyoto University, Japan). KYSE150 and KYSE510
were established from female patients, and KYSE30,
KYSE180, KYSE450 and YES2 were from male patients.
Each cell line was cultured in RPMI-1640 (Invitrogen,
USA) supplemented with 10% fetal calf serum (FCS).
ESCC tissue samples were procured from Chinese Acad-
emy of Medical Sciences Cancer Hospital. All the sam-
ples used in this study were residual specimens collected
after diagnosis sampling. And all patients received no
treatment before surgery, and signed separate informed
consent forms for the sampling and molecular analyses.
This study has been approved by the Ethics Committee/
IRB of Cancer Institute (Hospital), PUMC/CAMS.
Metaphase chromosomes and interphase cell nuclei
preparations
Metaphase chromosomes from ESCC cell lines and nor-
mal peripheral blood lymphocytes were harvested after in-
cubation with 0.04 μg/ml Colcemid (Invitrogen) at 37°C
for 1-2 hours, followed by treatment with a hypotonic so-
lution (0.075 mol/L KCl) for 30 minutes and three succes-
sive changes of the fixative solution (methanol/acetic acid,
3:1). ESCC tissue samples were cut into small pieces in
phosphate-buffered saline (PBS), and the interphase nuclei
were then prepared following the procedures described
above. Metaphase chromosomes and interphase cell nuclei
in suspensions were stored at 4°C overnight and then
stored at -20°C until use. The nuclear suspensions were
dropped onto clean slides and aged at room temperature
for 2-3 days prior to the FISH experiments.
Fluorescence in situ hybridization (FISH)
M-FISH was performed on the metaphase spreads. The 24-
color whole chromosome painting (WCP) and arm-specific
probes were directly labeled with diethylaminocoumarin
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(Abbott Molecular, USA), Cy3-dUTP (GE Healthcare,
USA) or Alexa594-dUTP (Invitrogen) by degenerate
oligonucleotide primed-polymerase chain reaction
(DOP-PCR) [39] or were indirectly labeled with Biotin-
11-dCTP (Invitrogen). Biotin was then visualized with
streptavidin-conjugated Cy5 (Jackson Immunoresearch
Laboratories Inc., USA). The 12-color FISH probes
were labeled with Green-dUTP, Cy3-dUTP, Alexa594-
dUTP and Cy5-dUTP.
Split regions were detected using dual-color break-
apart bacterial artificial chromosome (BAC) DNA clone
probes, which were labeled with Green-dUTP and Cy3-
dUTP by random priming using BioPrime DNA labeling
system (Invitrogen). BAC DNA clones were selected
according to their descriptions in Ensembl database
(www.ensembl.org). BAC DNA clones used to detect
splitting of 11q13.3-q13.4 and associated regions
included NONSC16D6 (68,072,319-68,278,585, hg18),
Cancer_1D11 (69,162,501-69,323,924, hg18), NONSC2E5
(70,236,623-70,391,405, hg18), NONSC3C5 (71,992,715-
72,182,751, hg18) and NONSC15F5 (75,107,934-75,273,492,
hg18).
The slides for M-FISH and dual-color break-apart
FISH analyses were pretreated with RNase A (100 mg/
ml in 2 x saline sodium citrate [SSC]) and pepsin (50
mg/ml in 0.01 mol/l HCl). The slides were subsequently
denatured in 70% formamide/2 x SSC at 73°C-75°C for 3
minutes, quickly cooled with two rinses of 2 x SSC at
4°C, dehydrated in a gradient series of ethanol (75%, 85%
and 100%), and air dried. The labeled probes were preci-
pitated, and redissolved in the hybridization solution
(50% formamide, 10% dextran sulfate, 1% Tween-20, 2 x
SSC), denatured at 75°C for 8 minutes, and quick-chilled
on ice for 2 minutes. Hybridization was performed in a
humid chamber at 37°C for 24-48 hours. Post-
hybridization washes were performed in 50% formamide/
2 x SSC for 15 minutes at 43°C and were performed
twice for 3 minutes each in 2 x SSC. The slides were
dehydrated in 75%, 85% and 100% ethanol, air dried,
counterstained with 40,6-diamidino-2-phenylindole (DAPI)
(1 mg/ml) and covered with coverslips.
For 12-color FISH analysis [28], the slides were hybri-
dized twice on metaphase spreads as previously
described, which was named two-round FISH. After
digital fluorescence image acquisition, coverslips on the
slides were removed by dipping in 100% ethanol for 30
min, and washed twice in 100% ethanol for 3 min each
time, then air dried, and then the slides could be dena-
tured as the above procedures.
Microscopy and digital image analysis
FISH images were captured using a Zeiss Axio fluores-
cence microscope equipped with a cooled charged-coupled device (CCD) camera (Princeton Instruments,
USA) or a JAI M4 Plus CCD camera (Metasystems
International, Germany). All of the fluorescent images
were captured with individual single-band-pass filters
specific for visualizing DAPI, DEAC, Green, Cy3, Alexa
594 and Cy5 fluorochromes. Pseudo-color images were
constructed and analyzed using MetaMorph (Universal
Imaging Corporation, USA) or Metacyte module of
Metafer imaging systems (Metasystems International).
Genomic DNA isolation and oligo array-based
comparative genomic hybridization (array-CGH)
Genomic DNA from ESCC cell lines was isolated using
DNeasy Blood & Tissue Kit (Qiagen, Germany).
Genome-wide copy number studies were then per-
formed using an Agilent 44K oligo array platform (Agi-
lent Technologies, USA), with sex-matched normal
human DNA (Promega Corporation, USA) used as the
reference. Briefly, 1 μg samples of the tested and refer-
ence DNA were digested with AluI and RsaI, and differ-
entially labeled with Cy3-dUTP and Cy5-dUTP using
Agilent Genomic DNA Enzymatic Labeling Kit Part
Number 5190-0449 (Agilent Technologies), respectively.
Then Microcon YM-30 (Millipore) was used to clean up
the labeled probes. Tested and reference DNA probes
were combined and hybridized onto the microarrays
enclosed in Agilent SureHyb-enabled hybridization
chambers for 40 hours. After hybridization, slides were
washed sequentially and scanned with an Agilent DNA
Microarray Scanner. Annotations for the probes were
based on UCSC hg18 (NCBI Build 36). CNAs and break-
point data were analyzed via the Agilent Genomic
Workbench Software 5.0, set to use the ADM-2 algo-
rithm, an aberration threshold of 5.0 and an absolute
average log2 ratio ≥ 0.5.
Statistical analysis
Statistical analyses were carried out by using the SPSS
17.0 software package. The association between splitting
of breakpoint regions and clinico-pathological character-
istics were assessed by the χ2 test, Fisher’s exact test or
Kruskal–Wallis test. Logistic regression analysis was per-
formed to determine the independent predictors of




M-FISH was performed on the metaphase chromosomes
of four ESCC cell lines (KYSE30, KYSE150, KYSE510
and YES2). Modal karyotypes of the cell lines are shown
in Figure 1. M-FISH karyotypes of two other cell lines
KYSE180 [28] and KYSE450 [29] have been previously
reported by our laboratory. We found multiple
Figure 1 M-FISH profiling of ESCC cell lines. A 24-color analysis technique was used for KYSE30 (A), KYSE150 (B), and YES2 cells (C) and 12-
color detection was used for KYSE510 cells (D).
Hao et al. BMC Cancer 2012, 12:367 Page 4 of 17
http://www.biomedcentral.com/1471-2407/12/367numerical alterations in the six cell line, which exhibited
high level of aneuploidy. An overview of CNAs indicated
that imbalances occurred throughout the entire genome
of the cell lines. Gains were observed at 1p, 1q, 3p, 3q,
4p, 5q, 7p, 8q, 9q, 11q, 14q, 16p, 16q, 17p, 17q, 18p,
19p, 19q, 20q, and 22q. Losses were primarily detected
at 3p, 4p, 4q, 6p, 6q, 9p, and 18q.
The detail CNAs of these cell lines were detected by
array-CGH, and the profiles of gains and losses are
shown in Figure 2 and Additional file 1: Table S1. Our
results were compared with the data available from
Cancer Cell Line Project on the Wellcome Trust San-
ger Institute Cosmic website (http://www.sanger.ac.uk/
genetics/CGP/cosmic). Copy number data of KYSE150,
KYSE450 and KYSE510 on the website were analyzed
using Affymetrix SNP6.0 arrays. Copy number profiles
derived from our Agilent 44K platform are very similar
to those from the Affymetrix platform. We then com-
pared CNAs among the six cell lines according to the
array-CGH data, and frequent gains and losses in at
least two cell lines were summarized in Table 1. More
gains were found than losses. The results were com-
bined with the data from other 17 ESCC cell lines
available on Cosmic website, including KYSE70,
KYSE140, KYSE270, KYSE410, KYSE520, Colo-68N,
EC-GI-10, HCE-4, TE-1, TE-5, TE-6, TE-8, TE-9, TE-
10, TE-11, TE-12 and TE-15. The gains with high fre-
quencies were shown in Additional file 2: Table S2.Regions with average log2ratio values greater than 1
were defined as amplifications. High-level amplifications
(HLAs) and homozygous deletions (HDs) were identified
if the absolute average values were no less than 2.
According to the positions of HLAs and HDs boundar-
ies, the smallest HLA and HD regions and involved
genes among these cell lines were listed in Table 2.
HLAs include 7p11 (2/6, 33%), 8q24.21 (2/6, 33%) and
11q13.3-q13.4 (3/6, 50%), harboring several oncogenes,
including EGFR, MYC and CTTN (Table 2). Homozy-
gous deletion of 9p21.3, containing tumor suppressor
genes CDKN2A, CDKN2B and CDKN2B-AS1, occurred
in 67% (4/6) of the cell lines.
Unbalanced breakpoints
Breakpoints were restricted to the boundaries between
two adjacent DNA fragments with significantly distinct-
ive log2 ratio values, reflecting different copy numbers.
Using this scheme, 261 candidate unbalanced break-
points were identified (Additional file 3: Table S3).
Among these candidates, 39 occurred in the centromeric
regions, and the other 224 were present on chromosome
arms. Fifty-seven of arm breakpoints were localized in
the vicinity of fragile sites. Breakpoints on chromosome
arms and copy number status of the regions at both
sides of the breakpoints were listed in Additional file 3:
Table S3. Cell lines were ranked according to the num-
ber of breakpoints, and the top three were KYSE30,
Figure 2 CNAs and unbalanced breakpoints in six ESCC cell lines detected by array-CGH. Gains and amplifications are presented as lines
on the right side of the chromosomes, while the lines for losses and deletions are on the left side. Unbalanced breakpoints are at the boundaries
of CNAs. Numbers on top of the lines are indicated as the cell lines. 30: KYSE30, 150: KYSE150, 180: KYSE180, 450: KYSE450, 510: KYSE510, 2: YES2.
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similar to that in M-FISH results.
Chromosomal structural aberrations
M-FISH results of four cell lines (KYSE30, KYSE150,
KYSE510 and YES2) as well as that of the previously
reported two cell lines (KYSE180 and KYSE450) showed
that a total of 156 derivative chromosomes resulted fromtranslocations, most of which were unbalanced; only
12.8% (20/156) were reciprocal. Approximately, 35% of
the translocation derivative chromosomes were fused at
the centromeric regions. Chromosomes 1, 2, 3, 5, 6, 7, 8,
9, 11, 12, 14, 15 and X were frequently rearranged. Com-
bining M-FISH with array-CGH, we further character-
ized multiple rearrangements present in these cell lines
(Table 3). KYSE30 is the cell line with the most complex
Table 1 Frequent gains and losses in six ESCC cell lines
analyzed by array-CGH
CNAs Positive
No. of cell lines
Region




3-4 1q21.1-q31.1, 2p24.1-p11, 3q13.31-q26.33,





17p13.1-p11, 17q, 20q11-qter, 20q13.12-qter
2 1pter-p36.13, 1p35.2-q31.1, 1p22.2-q31.1,





16q11-qter, 17pter-p11, 18q11-q12.2, 22q
Loss ≥5 18q21.1-qter
3-4 3p14.1-p11, 4p15.32-p14, 4q22.1-q32.3,
9pter-p24.1, 9p23-p11, 11q23.3-qter,
18q12.2-q21.1, Xpter-p11, Xq21.1-q23
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http://www.biomedcentral.com/1471-2407/12/367rearrangements, and array-CGH results have also indi-
cated that much more breakpoints were present in
KYSE30 than the other cell lines, which are consistent
with M-FISH results.
Recurrent breakpoint regions in ESCC cell lines and
primary tumor tissues
Positions of the breakpoints were compared among dif-
ferent cell lines, and further the distances of near break-
point regions were calculated. Five regions (11q13.4,Table 2 High level amplifications and homozygous deletions
CNAs Region a Cell line
HLA 7p11 KYSE30, KYSE450
8q24.21 KYSE450, KYSE510
11q13.3-q13.4 KYSE30, KYSE180, KYSE510
HD 9p21.3 KYSE180, KYSE450, KYSE510, YES2
HLA: high level amplification; HD: homozygous deletion; the Start and Stop position
a Regions of amplifications or deletions in at least two cell lines.9p21.3, 15q25.3, 3q28 and 10q26.3) had breakpoints less
than 1 Mb apart, and twelve (11q13.3, 4p13, 11p13,
8q24.21, 2q35, 1q31.1, 21q21.1, 9p21.3, 18q12.2, 3p14.2,
3q12.1-q12.2 and 6p12.3-p12.2) had breakpoints less
than 2 Mb apart in different cell lines (Table 4). For ex-
ample, breakpoints at 11q13.4 were detected in KYSE30
and KYSE510, while breakpoints at 11q13.3 were
detected in KYSE30 and KYSE180 (Figure 3A). The
three cell lines presented gain of 11q and amplification
of 11q13, in which copy numbers of the regions flanking
centromere to 11q13 amplicon was higher than the re-
gion distal to the amplicon. Losses of the region distal to
11q13 were also found as del(11q13.4-qter) in KYSE30,
del(11q14.3-q21) and del(11q22.3-qter) in KYSE510.
Translocations of highly amplified regions were also
observed (Table 3).
Genes which might be interrupted by the recurrent
breakpoints in each cell line were listed in Table 4. Ten
of these common breakpoint regions were localized in
the vicinity of fragile sites. Genes in these cell lines with
inner breakpoints included CDKN2A, LEPREL1, JAK-
MIP3, LIMCH1, CSTF3, ABTB2, CDKN2B-AS1, FHIT
and ABI3BP. For these genes, one breakpoint could be
detected. Small HDs were also observed inside some
genes, resulting in two breakpoints, such as FHIT gene
in KYSE450. Other genes flanking or close to the bound-
aries might also be influenced by the breakpoints.
To determine whether genomic aberrations found in
these cell lines are also present in primary tumors, we
first tested a small sample of 15 ESCC tumors by dual-
color FISH. This analysis revealed splitting of regions
11q13.3-q13.4, 9p21, 15q25.3 and 3q28, which presented
the highest frequency of disruption in the cell lines.
Splitting of these regions had occurred in 5, 1, 2 and 3
out of 15 tumors, respectively. We also examined online
data of ESCC cell lines. The results showed that both
high level amplifications and breakages existed at 67-72
Mb positions in 11q13 (Figure 3). Multiple breakpointsin different cell lines
Start Stop Genes
54572103 57613746 VSTM2A, SEC61G, EGFR, LANCL2,
VOPP1, FKBP9L, ZNF713, MRPS17,
GBAS, PSPH, CCT6A, SUMF2, PHKG1,
CHCHD2, ZNF479, ZNF716
128548643 129216964 POU5F1B, LOC727677, MYC, PVT1
68232360 70964483 MTL5, CPT1A, MRPL21, IGHMBP2,
MRGPRD, MRGPRT, TPCN2, MYEOV,
CCND1, ORAOV1, FGF19, FGF4,
FGF3, ANO1, FADD, PPFIA1,
CTTN, SHANK2, DHCR7, NADSYN1,
KRTAP5-7, KRTAP5-8, KRTAP5-9,
KRTAP5-10, KRTAP5-11
21958099 22136626 CDKN2A, CDKN2B, CDKN2B-AS1
s are annotated by hg18.
Table 3 Chromosomal structural aberrations analyzed by a combination of M-FISH and array-CGH
Cell line Chromosomal structural aberrations
KYSE30 der(1)t(1;8)(p10;q?), der(1;9)(p10;p10), der(1)(3qter! 3q?::5p11! 5p14.1::1p35.3! 1q23.2::17p10! 17p13.1:),
der(2;4)(4pter! 4p10::2pter! 2q31.2::4q10! 4qter), der(2)t(2;9)(p10;q22.3), der(2)t(2;X)(p10;p11),
der(2)(5pter! 5p14.1::2p16.2! 2q31.2::8q10! 8qter), der(3)t(3;9)(3q10!qter::9q22.1!q22.33:), der(4)t(4;5)(q10;p11),
der(4)t(4;7)(q13.3;p15.1), der(4)(4pter! 4p10::3q26.33! 3qter::7p12.1! 7p11::14q?), der(5)t(1;5)(p36.13;p10), der(5;11)(q10;p10),
der(5)(3q?! 3qter::5q10! 5q15::1q23.2! 1qter), der(5)(3q26.33! 3qter::5p14.1! 5p10::9q22.1! 9qter), der(5)(5pter!
5p10::11q13.3! 11q13.4::20q11! 20q11.23:), der(5)(:5p14.1! 5p10::13q?::18q11:), der(6)t(4;6)(q?;p24.1), der(7)t(6;7)(p22.3;p14.3),
der(5;7)(:5p14.1! 5p10::7p14.3! 7q22.1::12p10! 12pter), der(7)(16pter! 16p11;14q?;7p12.1! 7q22.1:), der(15)(9q22.3!
9qter::15q10! 15qter), der(11)t(6;11)(p10;p12), der(11;18)(p10;p10), der(7;11)(:11q10! 11q13.3::7q10! 7q22.1::12q11! 12q14.1:),
der(12;19)(p10;p10), der(12)(12pter! 12q14.1::19p?::18p?), der(13;19)(q10;q10), der(17)(:13q21.32! 13q31.3::17p13.1!
17p10::13q21.32! 13q31.3::17p13.1! 17p10:), der(14;20)(q10;p10), der(?)(14q?::16p?::7p11! 7p12.1:), der(14)(18pter!
18p10::13q?::14q10! 14q31.1:), der(15)t(5;15)(q15;q10), der(16;20)(q10;p10), der(16)(16pter! 16p10::10pter! 10p11.21::2q11!
2q33.1::?), der(17)(:7p12.1! 7p11::17q10! 17qter::17q10! 17qter), der(17;20)(:17p13.1! 17p10::22q10! 22q11.21::10q26.3!
10qter), der(17)(:18q11::9q22.1! 9q22.33::17p?! 17p10::22q12.1! 22q12.3::10p11.21! 10pter), der(21)t(5;21)(q15;q10),
der(21)t(9;21)(q22;q10), der(21)(:9q22.1! 9q22.33::11q13.3! 11q13.4::21q10! 21qter), der(22)t(7;22)(p12.1;q10)
KYSE150 der(1)t(1;14)(q31.1;q1?), der(2)(2pter! 2p24.3::1q32.2! 1q41::2p24.1! 2q35:), der(3)t(3;12)(p14.2;q14.1), der(5;11)(q10;p10),
der(6)t(6;X)(q?;q27.1), t(15;6;15;6;15)(:15q11::6p22.2! 6p21.33::15q10! 15q11::6p12.2! 6p12.1::15q11:), der(7)t(7;11)(p10;q?),
der(7)t(7;15)(q22.1;q11), der(5;7)(1pter! 1p22.2::7q10! 7q22.1::18q21.1! 18q21.1::5p10! 5pter), der(6;8)(p10;q10),
der(8)t(8;18)(p22;p11), der(9)(:9p24.1! 9p23::1q32.3! 1q41::9p21.1! 9qter), der(9)(9pter! 9q?::15q11! 15qter::7q?! 7qter),
der(11;19)(q10;p10), der(11)t(11;X)(p14.1;q10), der(11)(:2q35::11p14.1! 11p10::6p22.2! 6p21.33:), der(12)t(1;12)(?;q14.1), der(12)
(1pter! 1q31.1::9p2?! 9p2?::12p10! 12pter), t(21;11;12)(?::q?::q?!qter), der(13)t(5;13)(?;q10), der(?)(7q?::14q23.2!
14qter::15q10! 15q11:), der(14)(2qter! 2q35::11p1?! 11p1?::14q10! 14qter), der(15;22)(15q10! 15qter::22q10!
22qter::15q10! 15qter), der(16)t(12;16)(?;pter), der(17;20)(p10;q10), der(18)t(3;18)(p14.2;q10), der(6;19)(q10;p10),
der(X)t(11;X)(p14.1;p10), t(X;15;X)(?::15q?::?)
KYSE510 der(2)t(2;8)(q10;q23.3), der(2;9)(q10;q10), der(2)t(2;19)(p10;q1?), der(2)t(2;20)(q33.1;q?), der(2)(2pter! 2p10::18q12.1! 18q12.2::16p?),
der(3;6)(q10;p10), der(4)t(1;4)(p21.1;q10), der(4)t(4;17)(q34.3;?), der(5)(5pter! 5p10::19q13.11! 19q13.42::11q22.2!
11q22.3::15q25.3! 15qter::7pter! 7p12.3), der(7;10)(10q10! 10qter::7q10! 7q21.2::14q22.1! 14q31.1:),
der(8)(8pter! 8q12.1::1q21.2! 1q23.3::18q12.1! 18q12.2::1q21.2! 1q23.3:: 8pter! 8q12.1), der(9)(9q10! 9qter::8q23.3!
8q24.21::11q13.2! 11q13.4::15q25.3! 15qter::11q11! 11q13.2:), der(10)t(10;19)(q10;q12), der(11)t(11;18)(p10;q11),
der(11)(5pter! 5p11::11p13! 11q14.3::18pter! 18p11.31), der(14)t(9;14)(p11;q10), der(14)(14q?::3q28! 3qter::14q22.1!
14q31.1::14q?), der(15)t(15;21)(q10;q?), der(17)t(14;17)(?;q10), der(18)(:1q21.1! 1q23.3::18pter! 18p10::1q23.3! 1qter),
der(11)(9pter! 9p21.3::19q13.11! 19q13.42::8pter! 8p21.3::11q13.2! 11q13.4::15q25.3! 15qter::11q10!q?),
der(20)t(2;20)(q33.1;q10), der(21)t(15;21)(q25.3;q10), der(21)(:11p13! 11p11::2p11! 2p11::21q10! 21q?), der(X)t(3;X)(p14.1;p22.31)
YES2 der(3)t(3;12)(q29;?), der(3)(9pter! 9p21.3::3q10! 3q13.31::?), der(4)t(4;16)(q?;p11), der(5)t(5;9)(q?;?), der(5)t(5;13)(p10;q32.1),
der(6)t(6;20)(p12.3;q10), der(12)(16pter! 16p11::6p21.1! 6p12.3::12q10! 12q21.1:), der(7)t(7;12)(q11.21;q24.11),
der(17)t(7;17)(q31.1;p10), der(22)t(7;22)(q11.21;q10), der(10)t(10;16)(p10;p11), der(11)t(11;13)(p10;q32.1), der(11)t(11;21)(pter;?),
der(12)t(5;12)(q23.3;p10), der(12)t(12;20)(q21.1;q?), der(12)(12pter! 12p10::17q2?::8q23.3! 8q24.1:), der(13)(9q21.32!
9qter::13q10! 13q32.1::?::4q?), der(14)(14pter! 14q12::X?::12q?::14q22.1! 14qter), der(15)(15qter!q10::15q10! 15qter),
der(16)t(16;18)(p10;q11), der(16)t(16;X)(q11;?), der(17)(:17q10! 17q24.3::20q11.21! 20q?), der(20)(:16p11!
16p11::11p13! p11::20p10! 20pter), der(21)t(5;21)(q10;q21.1), der(X)t(22;X)(q11;p10)
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tions may be highly rearranged.
Due to the highest splitting frequency of 11q13.3-
q13.4 in the initial 15 cases, we further expanded the
sample pool to further characterize splitting of this re-
gion in primary ESCC cases (Figures 3B and 3C). Split-
ting frequencies of 11q13.4 and 11q13.3 were 36.6%
(49/134) and 23.4% (32/137), respectively. Overall,
breakage of 11q13.3-q13.4 was observed in 58 out of
134 cases (43.3%). Next, we divided the whole 11q13.3-
q13.4 region into several parts, including 11q13.3(1)
(CPT1A, MRPL21, IGHMBP2, MRGPRD, MRGPRF,
TPCN2, MYEOV), 11q13.3(2) (CCND1, ORAOV1,
FGF19, FGF4, FGF3, ANO1, FADD, PPFIA1, CTTN and
SHANK2), 11q13.4(1) (DHCR7, NADSYN1, KRTAP5-7,
KRTAP5-8, KRTAP5-9, KRTAP5-10, KRTAP5-11,
FAM86C1, DEFB108B, RNF121, IL18BP, NUMA1,
LRTOMT, FOLR3, FOLR1, FOLR2, INPPL1, PHOX2A
and CLPB). Regions of 11q13.3(1), 11q13.3(2), 11q13.4
(1), 11q13.3(2)-q13.4 and 11q13.3(2)-q13.4(1) were splitin 16.3% (22/135), 8.4% (11/131), 24.1% (32/133), 41.0%
(55/134) and 30.0% (39/130) of the primary ESCC
tumors, respectively. Almost all of the array-CGH
images of the cell lines in Figure 3A and Additional file
4: Figure S1 showed amplification of the region prox-
imal or distal to the breakpoints. Similarly, most of the
splitting-positive ESCC tumors examined by FISH pre-
sented focal high-level amplification of the region. The
majority of breakpoints between NONSC16D6 and
Cancer_1D11 were proximal to the amplicon, while
most of the breakpoints between Cancer_1D11 and
NONSC2E5 as well as those between NONS2E5 and
NONSC15F5 were distal to the amplicon (Figure 3C
and Additional file 5: Table S4).Correlations between split and amplified regions and
clinicopathological characteristics
Clinicopathological parameters of each patient were
listed in Additional file 6: Table S5, and the relationships
Table 4 Recurrent breakpoint regions analyzed by array-CGH in ESCC cell lines






9p21.3 a KYSE180 Neutral/Del 21958099-21968346 115.1 kb C9orf53 }, CDKN2A *, CDKN2B †, CDKN2B-AS1 † FRA9C
KYSE450 Neutral/Del 21853263-21968346 MTAP }, C9orf53 }, CDKN2A *
KYSE510 Loss/Del 21958099-21968346 C9orf53 }, CDKN2A *, CDKN2B †, CDKN2B-AS1 †
YES2 Neutral/Del 21853263-21957548 MTAP }, C9orf53 †, CDKN2A †
15q25.3 KYSE450 Neutral/Gain 86361096-86429254 154.2 kb LINC00052 }, NTRK3 *, MRPL46 †, MRPS11 †
KYSE510 Neutral/Gain 86275066-86429254 LINC00052 }, NTRK3 *, MRPL46 †, MRPS11 †
11q13.4 KYSE30 Amp/Loss 70964483-71305189 340.1 kb KRTAP5-11 }, FAM86C1, DEFB108B, RNF121 † FRA11H
KYSE510 Amp/Neutral 70964483-71305189 KRTAP5-11 }, FAM86C1, DEFB108B, RNF121 †
3q28 KYSE180 Gain/Gain 191171376-191222891 517.0 kb TP63 }, LEPREL1 *, CLDN1 †
KYSE510 Neutral/Gain 191610761-191688399 CLDN1 }, CLDN16, TMEM207 †, IL1RAP†
10q26.3 KYSE30 Neutral/Gain 133045086-133476780 801.8 kb TCERG1L }, PPP2R2D †
YES2 Neutral/Gain 133795639-133846905 BNIP3 }, JAKMIP3 *, DPYSL4 †
11q13.3 KYSE30 Amp/Amp 69339391-69569221 1.05 Mb FGF3 }, ANO1 †, FADD † FRA11H
KYSE180 Amp/Amp 70182767-70386856 CTTN }, SHANK2 *, DHCR7 †
4p13 KYSE150 Amp/Loss 41832777-42109513 1.15 Mb SLC30A9 }, BEND4, SHISA3 †, ATP8A1 †
KYSE510 Neutral/Loss 40955943-41226036 UCHL1 }, LIMCH1 *, PHOX2B †
11p13 KYSE510 Neutral/Gain 33107818-33136537 1.2 Mb TCP11L1 }, PIGCP1 }, CSTF3*, HIPK3 †
YES2 Neutral/Gain 34278741-34307224 NAT10 }, ABTB2 *, CAT †
8q24.21 KYSE450 Amp/Neutral 129216964-129574570 1.23 Mb FAM84B }, POU5F1B, MYC †, PVT1 †
KYSE510 Amp/Loss 129972316-130159085 FAM84B }, POU5F1B, MYC †, PVT1 †
YES2 Amp/Neutral 130159144-130451718 far from genes, PVT1 }, GSDMC †
2q35 KYSE30 Loss/Neutral 217432472-218386863 1.37 Mb DIRC3 }, TNS1, CXCR2P1†
KYSE150 Loss/Gain 218517852-218801703 TNS1 }, CXCR2P1, CXCR2, CXCR1, HMGB1P9, ARPC2 †
1q31.1 KYSE150 Gain/Loss 186080345-186315797 1.40 Mb PLA2G4A }, FAM5C † FRA1K
KYSE450 Gain/Neutral 184912220-185051701 PTGS2 }, PLA2G4A †
21q21.1 KYSE30 Gain/Neutral 17060792-17145790 1.48 Mb USP25 }, C21orf34 }, CXADR †
YES2 Gain/Neutral 18435266-18540695 CHODL-AS1 }, CHODL †, TMPRSS15 †
9p21.3 b KYSE180 Del/Neutral 21999029-22136626 1.45 Mb CDKN2A *, CDKN2B, CDKN2B-AS1, DMRTA1 † FRA9C
KYSE450 Del/Neutral 21980581-21993651 CDKN2A *, CDKN2B, CDKN2B-AS1 *, DMRTA1 †
KYSE510 Del/Loss 22992377-23425976 DMRTA1 *, ELAVL2 †
YES2 Del/Neutral 21999029-22136626 CDKN2B, CDKN2B-AS1, DMRTA1 †
18q12.2 KYSE450 Gain/Loss 33583906-33747373 1.64 Mb CELF4 }, LOC647946 † FRA18A
KYSE510 Amp/Loss 32107441-32200063 MOCOS }, FHOD3, C18orf10 †
3p14.2 KYSE150 Gain/Loss 58573676-58887412 1.69 Mb FAM107A }, FAM3D, C3orf67, FHIT † FRA3B
KYSE450 Neutral/Del 59933661-60267262 FHIT #
3q12.1-q12.2 KYSE180 Neutral/Amp 100190484-100877203 1.86 Mb TFG }, ABI3BP*, IMPG2 †
KYSE450 Neutral/Gain 102009730-102076392 DCBLD2 }, COL8A1 †
6p12.3-p12.2 KYSE150 Loss/Amp 51932658-52161439 1.9 Mb PKHD1 }, IL17A †, MCM3 †
YES2 Gain/Gain 50261630-50627364 DEFB112 }, TFAP2D †
a Copy number status on the left and right side of the breakpoint regions. CN: copy number, Amp: amplification, Del: deletion.
b The distance between two outermost breakpoints of all the different cell lines.
c These genes are located at or close to breakpoints in each cell line. “*”: Obvious breakpoints were detected inside of genes. “}” and “†”: Genes at the left and
right side of the breakpoint regions, respectively. Genes that are not labeled are located in the breakpoint regions, but positions of the exact breakpoints are not
determined. “#”: Genes with an inside homozygous deletion (HD), and thus might also be disrupted.
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Figure 3 11q13.3 and 11q13.4 are recurrent breakpoint regions in both the ESCC cell lines and primary tumors. (A) Breakpoints in
11q13.3 and 11q13.4 in the cell lines detected by array-CGH. Breakpoints fall between the probes that displayed significant copy number
discrepancies (blue arrows). Amplifications are indicated with red signals. (B) The 1-Mb BAC clones that are used in dual-color FISH experiments
are shown in the ideogram. Also, 11q13.3 and 11q13.4 are divided into smaller regions according to the positions of BAC DNA clones: 11q13.3(1)
(from NONSC16D6 to Cancer_1D11), 11q13.3(2) (from Cancer_1D11 to NONSC2E5) and 11q13.4(1) (from NONSC2E5 to NONSC3C5). (C) Detection
of 11q13.3-q13.4 breakpoint regions by dual-color FISH in ESCC tumors. BAC DNA probes at two sides of the breakpoint regions are labeled with
Cy3-dUTP (red) and Green-dUTP (green). The BAC clones used for each region are listed beside the panel. Two examples of positive tumors are
shown for each region. “Tumor 1” and “Tumor 2” samples shown for different regions may not be from the same cases. Most splitting-positive
nuclei exhibited amplifications on one side, even high-level amplifications, revealing the breakages between red and green signals. Normal:
peripheral blood from normal persons.
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characteristics were summarized in Table 5. Splitting of
11q13.3-q13.4 was significantly correlated with lymph
node metastasis (LNM) (P= 0.004) and advanced stages
(P= 0.004). In LNM-positive group, 54.9% (39/71) of the
tumors exhibited splitting compared with 30.2% (19/63)
in LNM-negative group. Tumors at stages IIb/III/IV
(53.9%, 41/76) showed higher frequencies of splitting
than those at stages I/IIa (29.3%, 17/58). Breakpoint
regions of 11q13.4, 11q13.4(1), 11q13.3(2)-q13.4(1) and
11q13.3(2)-q13.4 were also associated with LNM and
advanced stages (P < 0.05, Additional file 7: Table S6).
No correlations were observed between splitting in these
regions and other clinico-pathological parameters, in-
cluding gender, age, tumor size, and differentiation
(Table 5 and Additional file 7: Table S6). We also testedthe relationship between amplification of this region and
clinical features. 11q13.3-q13.4 amplifications were
defined as the number of FISH signals was at least 3
(Additional file 5: Table S4). A positive correlation was
observed between 11q13.3-q13.4 amplification and LNM
(P= 0.022) or advanced stages (P= 0.039) (Table 5).
Amplification of 11q13.3 or 11q13.4 alone was not asso-
ciated with the parameters (Additional file 8: Table S7).
In order to create a multivariate model describing
the risk for LNM, univariate and multivariate logistic
regression analyses were performed with respect to
gender, age, tumor size, differentiation status, as well as
11q13.3-q13.4 splitting and amplification. Multivariate
analysis indicated that only splitting of 11q13.3-q13.4
was an independent predictor for LNM in ESCC
(P= 0.026, RR = 2.357, Table 6).
Table 5 Relationship between splitting and amplification
of 11q13.3-q13.4 and clinical features of primary ESCC
tumors
Clinical features Splitting Amplification
Frequency P value Frequency P value
Gender
Male 47.2% (50/106) 0.089 a 86.2% (94/109) 1.000 a
Female 28.6% (8/28) 89.3% (25/28)
Age
< 60 47.8% (33/69) 0.274 87.1% (61/70) 1.000 a
≥ 60 38.5% (25/65) 86.6% (58/67)
Tumor size
T1, T2 50.0% (10/20) 0.511 85.0% (17/20) 0.728 a
T3, T4 42.1% (48/114) 87.2% (102/117)
Lymph node metastasis
N0 30.2% (19/63) 0.004 79.4% (50/63) 0.022 a
N1 54.9% (39/71) 93.2% (69/74)
Stage
I, IIa 29.3% (17/58) 0.004 79.3% (46/58) 0.039 a
IIb, III, IV 53.9% (41/76) 92.4% (73/79)
Differentiation
G1 40.7% (11/27) 0.762 b 85.2% (23/27) 0.118 b
G2 41.7% (30/72) 91.9% (68/74)
G3 48.6% (17/35) 77.8% (28/36)
a Fisher’s test.
b Kruskal–Wallis test.
The P value which is not labeled with “a” or “b” is assessed by χ2 test.
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Genomic numerical and structural alterations are com-
mon features in ESCC. Our study characterized CNAs,
structural aberrations, and recurrent breakpoints in six
ESCC cell lines by a combination of M-FISH and array-
CGH analyses, which helps provide accurate karyotypes
of these cell lines. We further found the correlation be-
tween splitting of an amplified region 11q13.3-q13.4 and
lymph node metastasis.
Genomic CNAs may influence gene expression
through the following mechanisms. A well known
mechanism is that gains or losses may result in gene
amplifications or deletions, and thus upregulate or
downregulate the protein expression [40]. Different
situations may occur on genes at the boundaries of
gain or loss regions. CNA boundaries inside of the
genes usually indicate gene breakage. Gene rearrange-
ments may result from such breakages, leading to the
formation of an aberrant gene product [41]. If the
CNA boundaries occur in non-coding regions flanking
genes, expression may be controlled by proximity to
regulatory sequences from other genes. Alternatively,
the recurrent breakpoint may indicate loss of a tumorsuppressor gene distal to the CNA boundary [42].
Small deletions inside of the genes may result in struc-
tural aberrant proteins, truncated proteins, or even
loss-of-function proteins. Small amplifications and dele-
tions inside of genes may also indicate gene breakage,
and the gene products may also be affected by rearran-
gements with the partner gene. On the other hand,
many recurrent rearrangements occurred at boundaries
of the breakpoints, resulting in fusion genes, truncated
genes, as well as other structural variants [2]. There-
fore, we focused on the breakpoints with CNAs
involved in genomic rearrangements and breakpoints
mapped to specific sites.
Copy number profiling of ESCC have been analyzed
from different studies. Gains involved regions 5p, 7p, 7q,
8q, 11q, 12p, 14q, 16p, 19q, 20q and have been reported
in ESCC cell lines by SKY and CGH [35], as well as at
least 60% primary tumors by 32K array-CGH [36]. Re-
cently, gains of 19p13.3-q13.43, 11q13.1-q13.4, 20p13-
q13.33, 3q24-q29, 22q11.21-q12.1 have been reported
[38]. We detected six cell lines, and compared with on-
line database, the high frequency of gains mainly include
3q26.33-qter, 5p14.1-p11, 7pter-p12.3, 8q24.13-q24.21,
9q31.1-qter, 11p13-p11, 11q11-q13.4, 17q23.3-qter,
18pter-p11, 19p, 19q and 20q13.32-qter. Gain of 3q is
prevalent in ESCC, and 3q26-qter was found in 76.5%
(39/51) primary tumors [43] and 66.7% (4/6) cell lines
[44], suggesting cancer-related genes may be present in
3q26-qter. Evidence has been found that PIK3CA
[35,45], PRKCI [46], and ZNF639 [47] are amplified and
overexpressed in ESCC. PIK3CA [45] and PRKCI [46]
are associated with LNM and overexpression of PIK3CA
and TFRC are associated with poor prognosis [48]. We
found gain of 5p14.1-p11 existed in 83.3% (5/6) cell
lines. In the previous study, gain of 5p13 was detected in
10% (3/29) ESCC cell lines. SKP2 on 5p13 was amplified
and overexpressed in 50% (23/46) ESCC tumors, and
was associated with LNM and stage. SKP2 overexpres-
sion could protect cancer cells from anoikis, which was
mediated in part by the phosphoinositidyl 3-kinase-Akt
pathway [49]. Gains of 18p11.2-p11.3 and 18p11.3 were
also found in 20.7% and 17.2% cell lines by CGH [31]
and FISH [50]. AURKA at 20q13 encodes a cell cycle-
regulated kinase. Yang et al. found that overexpression
of AURKA was existed in 85.7% (6/7) cell lines and
93.1% (27/29) tumors [51]. Recent studies have reported
that AURKA is a direct target of the MAPK pathway
[52]. Overexpression of AURKA is independently asso-
ciated with chromosomal instability in colorectal cancer
[53], and AURKA expression has a prognostic value in
ovarian carcinoma [54]. High-level amplifications of
11q13.3-q13.4, 7p11.2, and 8q24.21 have been observed
in this study. Amplification of 11q13.3-q13.4 will be dis-
cussed later. Amplification of 7p11.2, which harbors an
Table 6 Logistic regression analyses of the impact of clinico-pathological factors and 11q13.3-q13.4 splitting and
amplification on LNM
Clinical features LNM Univariate analysis Multivariate analysis
N0 N1 P value RR (95% CI) P value a RR (95% CI)
Gender
Male 48 61 0.368 1.466 (0.637-3.374) -
Female 15 13
Age
< 60 32 38 0.948 0.978 (0.499-1.915) -
≥ 60 31 36
Tumor size
T1, T2 11 9 0.384 1.528 (0.589-3.964) -
T3, T4 52 65
Differentiation




Non-splitting 44 32 0.004 2.822 (1.384-5.757) 0.026 2.357 (1.110-5.004)
Splitting 19 39
Amplification status
Non-amp 13 5 0.022 3.588 (1.202-10.712) 0.165 2.265 (0.715-7.175)
Amp 50 69
a The P value of each variable which is not significantly correlated with LNM in univariate analysis is indicated with “-” in the multivariate analysis. Multivariate
logistic regression analysis is performed using forward procedures.
LNM: lymph node metastasis; RR, relative risk; CI, confidence interval; amp: amplification.
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http://www.biomedcentral.com/1471-2407/12/367important oncogene EGFR, was also found in ESCC
from other studies [36]. Amplification and overexpres-
sion of EGFR gene may play roles in the invasion and
progression in cancer [55], and the elevated expression
may be an indicator for tumor recurrence and lower sur-
vival in head and neck squamous cell carcinoma
(HNSCC) [56]. Amplification of MYC in 8q24.21 may
contribute to the progression of breast cancer [57].
Losses were previously found on 3p, 5q, 8p, 9p and 11q
[36], as well as 4p16.3-q35.2, 13q12.11-q34, 18p11.32-q23,
and chromosome Y [38]. In our study, losses were observed
on 18q12.2-qter, 3p14.1-p11, 4p15.32-p14, 4q22.1-q32.3,
9pter-p24.1, 9p23-p11, 11q23.3-qter, 18q12.2-q21.1, Xpter-
p11, Xq21.1-q23 in more than 50% (3/6) of the cell lines,
indicating several tumor suppressor genes may be located
in these regions. 9p21.3 (CDKN2A and CDKN2B) is
homozygously deleted in some of ESCC [58,59]. It has
been found that CDKN2A was fused to IGH through the
translocation t(9;14)(p21;q32) in a pre-B acute lympho-
blastic leukemia cell line [60]. The functional study
demonstrated that restoring wild-type CDKN2A into the
gene deleted ESCC cells significantly inhibited cell inva-
sion, suggesting that inactivation of CDKN2A may be
involved in ESCC invasion [59]. Our array-CGH resultsconfirmed that HD frequency of 9p21.3 was 66.7% (4/6).
Interestingly, CDKN2A was deleted in only one cell line,
and the other three harbored at least one breakpoint in-
side of CDKN2A. For CDKN2B, the inside breakpoint
was detected in one cell line, while the other three were
homozygously deleted.
Recurrent breakpoint regions were detected in at least
two cell lines, including 1q31.1, 2q35, 3p14.2, 3q12.1-
q12.2, 3q28, 4p13, 4q22.1, 6p12.3-p12.2, 6p22.2-p22.1,
7q22.2-q22.3, 8q24.21, 9p21.3, 10q26.3, 11p13, 11q13.3,
11q13.4, 13q21.32, 15q25.3, 18q12.2 and 21q21.1. Many
of these breakpoints were different from those detected
by SKY in other ESCC cell lines [35]. The correlation
between breakpoints of fusion genes and fragile sites has
been emphasized in previous studies. Burrow et al. ana-
lyzed 444 pairs of genes involved in cancer-specific re-
current translocations, and found that 52% of the
breakpoints in at least one gene of the fusion-gene pairs
were localized within the vicinity of a fragile site [61].
Thus, understanding breakpoints near fragile sites may
be helpful for further discovering cancer-related gene
rearrangements.
11q13 is an important region that presents various
aberrations in many malignancies. Gain of 11q13 has
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other solid tumors, including oral [42], gastric [64],
breast [65-67], ovarian [68], prostate [69], bladder [70],
laryngeal [71], nasopharyngeal [72], and liver tumors
[73] as well as head and neck [74,75] cancer. Gain fre-
quencies of 11q13 varied between studies. The probable
target genes that are amplified and/or overexpressed in
different cancers have been reported to include CCND1
[62,76,77], FGF4 [62,78], PPFIA1 [67], CTTN [62,76]
and ORAOV1 [79]. We observed that 11q13.3-q13.4 was
a region with high-level amplification adjacent to the
breakpoint boundaries. Breakpoints in 11q13.4 and
11q13.3 were both found in two cell lines, and break-
points that were identified in 11q13.4 between KYSE30
and KYSE510 were closer to each other. Furthermore,
breakpoints in the entire region of 11q13.3-q13.4 were
present in more than 40% of ESCC tumors, suggesting
that 11q13.3-q13.4 may be a frequently split region in
ESCCs.
11q13 is also involved in various chromosomal rear-
rangements in both hematological malignancies and epi-
thelial carcinomas. The t(11;14)(q13;q32) translocation is
associated with 70%-90% of mantle cell lymphomas
(MCL) [80,81], a small portion of multiple myeloma
(MM) [81,82], acute myeloid leukemia (AML) [83] and
other lymphoproliferative disorders [84]. As a result of
this translocation, CCND1 is fused to the enhancer of
immunoglobulin heavy chain gene (IGH), and thus over-
expressed in MCL and MM [81]. MYEOV, proximal to
CCND1, was also overexpressed in a subset of t(11;14)-
positive MM cell lines, in which both MYEOV and
CCND1 were under the control of IGH enhancers due
to translocations [85]. There are also other partner genes
fused to CCND1, including IGK involved in t(2;11)(p11;
q13) in leukemic small-cell B-non-Hodgkin lymphoma
(NHL) [86] and an unknown partner gene in AML with
t(5;11)(q35;q13) [87]. 11q13 rearrangements with 6p21,
7q11.2, 1p13 and 5q35 were observed in renal oncocy-
toma. Jhang et al. demonstrated that CCND1 was over-
expressed only in the cases with 11q13 translocation.
However, not all of the cases with 11q13 translocations
could lead to CCND1 overexpression [88]. Evidence of
fusions involving other genes in 11q13 has been
reported. NUMA-RARA and RUNX1-MACROD1 were
present in the monocytic leukemia with t(11;17)(q13;
q21) [89-91] and APL with t(11;21)(q13;q22) [92], re-
spectively. Rearrangement of LRP5 was found in AML,
although the partner gene has not been identified [93].
Most of the above translocations in lymphomas and
leukemia are balanced and not complicated, while more
complex rearrangements of 11q13 were detected in epi-
thelial carcinomas, including cervical carcinoma cell
lines [94], serous ovarian adenocarcinoma [95], hepato-
cellular carcinoma [96], gastric cancer [97] and oralsquamous cell carcinoma (OSCC) [98,99]. Our M-FISH
results were much similar to the observations in these
carcinomas. We found that chromosome 11 was fre-
quently rearranged, especially in KYSE30, KYSE150 and
KYSE510. In each cell line, five to six derivative chromo-
somes associated with chromosome 11 were easily
found, and some complex derivative chromosomes
involved q13 band of the chromosome. Genes involved
in breakpoints of these rearrangements remain to be
clarified.
The current array-CGH profiling enabled us to set the
boundaries of 11q13 amplicons in ESCC cell lines. We
observed that multiple breakpoints existed in high level
amplification regions involving 11q13.3 were located in
67-72 Mb position in three ESCC cell lines we detected
and ten online cell lines, which is similar to the amplifi-
cation peak in HNSCC [75]. The mechanisms for forma-
tion of several amplicons have been well described by a
model of breakage-fusion-bridge (BFB) cycle. According
to this model, the formation of amplicons is initiated by
distal DNA breakages at fragile sites. During DNA repli-
cation, a dicentric chromosome with an inverted dupli-
cation may be resulted from the sister chromatid fusion
(SCF). Breakage-fusion-bridge cycle may continue when
another break between two centromeres occurs. The
cycle may be then stabilized by a telomere or by trans-
location [42,98,100-102]. Albertson suggested that
amplicon boundaries might also be set by selection for
overexpressed genes in the amplicons, or by selection
against expression changes of genes outside of amplified
regions induced by CNAs [101,103]. 11q13 harbors three
fragile sites, FRA11A, FRA11H and FRA11F [104].
FRA11A is a rare fragile site, while FRA11H and FRA11F
are common fragile sites. FRA11A is located between
RIN1 (11q13.2) and CCND1 (11q13.3) [98]. FRA11H is
positioned at 11q13, but the exact location still needs to
be characterized. FRA11F is located between the BAC
clones of RP11-281H14 and RP11-841F15 in 11q14.2
[42]. Reshmi et al. found that OSCC cell lines with com-
plex 11q rearrangements were affected by FRA11F, and
gene amplifications in 11q13 region in OSCC cell lines
may be initiated by breakage at FRA11F [42]. Shuster
et al. demonstrated that breakages at FRA11A between
RIN1 and CCND1 may promote the BFB cycles [98].
They also found the involvement of FRA11H in some
OSCC cases with amplifications of genes in 11q13
[42,105]. In the present study, distal boundaries of
amplicons in the majority of ESCC cell lines and primary
tumors with 11q13 amplification were clustered within
67-72 Mb region of 11q13.3, which may involve FRA11H
breakages for these cases. Another breakpoint was
observed at NAALAD2 gene in KYSE510, and it was
located within FRA11F. In addition, breakpoints prox-
imal of 11q13 amplicons in KYSE180, KYSE510 and five
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11q13.3, while the proximal breakpoints in KYSE30 and
other online cell lines were distal to FRA11A or in
FRA11H. In the tested ESCC tumors, the majority of
breakpoints in 11q13.3(1) were proximal to the ampli-
cons, and most of those in 11q13.3(2) and 11q13.4 were
distal to the amplicons. Thus, we speculate that initial
distal breakages may primarily occur at FRA11H, and
the process may involve FRA11F in some cases. FRA11A
or FRA11H may contribute to setting amplicon bound-
aries by promoting subsequent steps of BFB cycle. Con-
cerning the presentation of multiple breakpoint
boundaries in some of ESCC cell lines and primary
tumors with high-level amplification of 11q13, several
cycles of random breakages may be undergone.
In the current study, we have noticed that copy num-
bers of the regions from centromere to boundaries at
initial breaks were higher than those of the regions distal
to breakpoints in most of ESCC cell lines with 11q13
amplifications. Gains of proximal regions, losses of distal
regions, intrachromosomal or interchromosomal rear-
rangements of 11q13 have been found in the cell lines
or primary tumors of human cancer and demonstrated
to be indicators of BFB cycle [98,101]. At the end of BFB
cycles, distal breakpoints of 11q13.3-q13.4 amplicon may
undergo intrachromosomal rearrangements or translo-
cating to other chromosomes, which may affect genes at
distal boundaries through forming intragenic rearrange-
ments or fusing to other genes. Notably, most of
11q13.3-q13.4 splitting cell lines according to our and
online array-CGH data showed high-level amplification
of 11q13 proximal or distal to the breakpoints in ESCC
cell lines and primary tumors. Moreover, amplicons in-
volving intrachromosomal or interchromosomal rearran-
gements have also been detected. Thus, recurrent
breakage at 11q13.3-q13.4 may reflect the following
aspects. On one hand, genes between two BACs flanking
the regions may be amplified, with proximal gain and
gene overexpression. On the other hand, breakages be-
tween two BACs and thus rearrangements of genes at
the amplicon boundaries may also dysregulate expres-
sion of these genes.
The relationship between gain of 11q13 and LNM or
prognosis have been analyzed and discussed in several
studies. However, contrary opinions still exist. Tada et al.
conducted CGH on 36 ESCC specimens, and demon-
strated that gain of 11q13 did not occur at a significantly
different rate between LNM and non-LNM groups
[106]. Genes located in 11q13 were analyzed. Amplifica-
tion of CTTN was correlated with LNM, while no sig-
nificant association was found between CCND1
amplification and LNM [76], however, predicting
CCND1 amplification using plasma DNA may be an in-
dependent prognostic factor in ESCCs [107]. Komatsuet al. found that overexpression of ORAOV1 showed a
significant association with LNM and stages. Gain of
11q13.2 was determined to be an independent prognos-
tic factor for predicting poor outcome, and amplification
of CPT1A in 11q13.2 was correlated with shorter overall
survival in ESCC. Here, we found the correlation be-
tween 11q13.3-q13.4 amplification and LNM as well as
advanced stages. The relationship between gene status in
11q13 and LNM has also been evaluated in other can-
cers. Amplification of 11q13 DNA is associated with
lymph node involvement in HNSCC [108]. CCND1
amplification and overexpression are significantly asso-
ciated with LNM and survival in OSCC [109]. Another
study confirmed amplifications of 11 genes in 11q13,
and found two amplification cores, including core 1
(TPCN2 and MYEOV), and core 2 (from CCND1 to
CTTN). Amplification of CTTN (core 2) and/or TPCN2/
MYEOV (core 1) was further demonstrated to be asso-
ciated with LNM in OSCC [110]. However, Huang et al.
reported that there was no correlation between LNM
and amplification or expression of the tested genes in
11q13 in OSCC [111]. Fortin et al. also found 11q13
amplifications not appear to be a reliable marker for
subclinical LNM prediction in oral and oropharyngeal
carcinomas [112]. A study by Xia et al. indicated that
amplifications of ORAOV1 and CTTN are indicated to
be associated with LNM [113]. In the breast cancer,
PPFIA1 is coamplified with CCND1, which is signifi-
cantly associated with high-grade phenotype but not
tumor stage or nodal stage [67].
In this report, we demonstrated that both of 11q13.3-
q13.4 splitting and amplification are significantly corre-
lated with LNM and advanced stages, indicating that
breakage and amplification of this region may play im-
portant roles in the tumor progression. According to
multivariate logistic regression analysis, however, it was
splitting rather than amplification that could be an inde-
pendent predictor for the higher tendency of metastasis.
In addition, two smaller regions 11q13.4(1) (SHANK2,
DHCR7, NADSYN1, KRTAP5-7, KRTAP5-8, KRTAP5-9,
KRTAP5-10, KRTAP5-11, FAM86C1, RNF121, IL18BP,
NUMA1, LRTOMT, FOLR3, FOLR1, FOLR2, INPPL1,
PHOX2A and CLPB) and 11q13.3(2)-q13.4(1) (CCND1,
ORAOV1, FGF19, FGF4, FGF3, ANO1, FADD, PPFIA1,
CTTN, SHANK2, DHCR7, NADSYN1, KRTAP5-7,
KRTAP5-8, KRTAP5-9, KRTAP5-10, KRTAP5-11, FAM86C1,
RNF121, IL18BP, NUMA1, LRTOMT, FOLR3, FOLR1,
FOLR2, INPPL1, PHOX2A and CLPB) and were also
associated with these parameters. However, no signifi-
cant difference was found for 11q13.3(1) (CPT1A,
MRPL21, IGHMBP2, MRGPRD, MRGPRT, TPCN2,
MYEOV). These results suggested that genes located in
11q13.3(2) and 11q13.4(1) may play more important
roles in LNM than 11q13.3(1). It will be interesting to
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by genomic breakages. Since the exact breakpoint loca-
tions may be distinctive in different cases, further studies
will be focused on determining which of these genes
were rearranged or disrupted in specific cases, identify-
ing possible rearranged forms and roles of these altera-
tions may play in ESCC development.Conclusions
Our data provide detailed information on chromosomal
and genomic aberrations present in six ESCC cell lines.
Using a combination of M-FISH and array-CGH enabled
us to produce more accurate karyotypes, which will help
to determine appropriate applications of these cell lines
for cytogenetic and molecular biological studies. The re-
current genomic breakpoints present in both the cell
lines and primary tumors may help to identify aberrant
genes associated with the development and progression
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